Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells $932,217.02 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the company’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $27.02, for a total transaction of $932,217.02. Following the completion of the transaction, the chief executive officer directly owned 15,558 shares in the company, valued at $420,377.16. The trade was a 68.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Performance

Shares of MAZE stock opened at $26.43 on Monday. Maze Therapeutics, Inc. has a 1-year low of $21.95 and a 1-year high of $53.65. The firm has a market cap of $1.47 billion, a PE ratio of -10.49 and a beta of 2.16. The company has a 50-day moving average of $26.97 and a two-hundred day moving average of $28.06. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, analysts predict that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Institutional Trading of Maze Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada boosted its position in shares of Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after acquiring an additional 1,383 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Maze Therapeutics in the second quarter valued at approximately $48,000. Quantbot Technologies LP acquired a new stake in Maze Therapeutics during the second quarter worth approximately $80,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Maze Therapeutics in the 4th quarter valued at $145,000. Finally, Squarepoint Ops LLC grew its position in shares of Maze Therapeutics by 42.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock valued at $580,000 after buying an additional 5,822 shares during the last quarter.

Analyst Ratings Changes

A number of research analysts have commented on MAZE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Monday, September 21st. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Maze Therapeutics in a research note on Thursday, September 24th. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Tuesday, September 22nd. Finally, Citigroup began coverage on Maze Therapeutics in a report on Wednesday, September 23rd. They set a “buy” rating and a $50.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $63.40.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic diseases. The company uses human genetics and its Maze Compass platform to identify disease-causing biological mechanisms and design small-molecule therapies intended to address the underlying drivers of disease.

Maze’s pipeline includes MZE001, an investigational oral therapy designed to inhibit glycogen synthase as a potential treatment for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles.